logo-loader
viewCrescita Therapeutics Inc

Crescita Therapeutics stock jumps as it swings to a profit in the first quarter

The revenue increase was driven by Crescita’s licencee, Taro Pharmaceuticals, reaching a contractual sales milestone as Pliaglis sales soared in the United States

pliaglis
Crescita is gearing up to commercialize Pliaglis throughout Italy, Portugal, France and Spain through a new agreement with Cantabria Labs

Crescita Therapeutics Inc (TSE:CTX) shares jumped Wednesday after the commercial dermatology company swung to a profit in the first quarter.

Shares of Crescita climbed 14.7% to $0.78 on the Toronto Stock Exchange in midday trade. The company’s stock is up  66% since the beginning of 2019.

For the quarter ended March 2019, revenue increased 16.4% to $4.2 million, up from $3.6 million during the same quarter a year ago. The company also posted a profit of $42,000, a dramatic reversal from the $424,000 loss during the same period a year ago. Crescita also ended the period with a $10.9 million cash balance.

READ: Acasti Pharma Inc receives new patents in Israel, Mexico and Chile as it advances its cardiovascular drug

Crescita owns a portfolio of non-prescription skincare products and has one FDA-approved prescription product, Pliaglis, that is licensed globally to Galderma SA and Taro Pharmaceuticals for the US market.

The revenue increase was driven by Crescita’s licencee, Taro Pharmaceuticals Inc, reaching a contractual sales milestone as Pliaglis sales increased in the US, which netted the company $1.3 million (US$1 million).

"I am pleased with the positive momentum our team has generated in the first quarter of fiscal 2019, as demonstrated by our revenue and Adjusted EBITDA growth, as well as our strong cash position," said Serge Verreault, president and CEO of Crescita. "We will remain focused on the fundamentals of our business to drive sustainable profitable growth in 2019."

Crescita is gearing up to commercialize Pliaglis throughout Italy, Portugal, France and Spain through a new agreement with Cantabria Labs, a leading prescription dermatology company in Europe.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

 

Quick facts: Crescita Therapeutics Inc

Price: 0.58 CAD

TSX:CTX
Market: TSX
Market Cap: $12.01 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen CEO details expansion of key coronavirus trial to patients in home

Synairgen PLC's (LON:SNG) CEO Richard Marsden caught up with Proactive London's Andrew Scott after announcing that the trial of its SNG001 interferon-beta treatment will be extended to coronavirus patients in the home environment. He says the idea behind the move is to dose patients with the...

10 hours, 50 minutes ago

2 min read